Suchergebnisse - "Fuchs, Ota"

PubPharm (36)

1

Association of HLA class I type with prevalence and outcome of patients with acute myeloid leukemia and mutated nucleophosmin

enthalten in: bioRxiv.org | 2023

von Kuželová, K. | Brodská, B. | Schetelig, J. | +9

2

Targeting cereblon in hematologic malignancies

enthalten in: Blood reviews | 2023

von Fuchs, O.

3

Multiple Myeloma

Erschienen: [Erscheinungsort nicht ermittelbar], IntechOpen, 2021

von Fuchs, O.

4

Preclinical Studies of PROTACs in Hematological Malignancies

enthalten in: Cardiovascular & hematological disorders, drug targets | 2021

von Fuchs, O. | Bokorova, R.

5

Preclinical Studies of PROTACs in Hematological Malignancies

enthalten in: Cardiovascular & hematological disorders drug targets | 2021

von Fuchs, O. | Bokorova, R.

6

Aberrantly elevated suprabasin in the bone marrow as a candidate biomarker of advanced disease state in myelodysplastic syndromes

enthalten in: Molecular oncology | 2020

von Pribyl, M. | Hubackova, S. | Moudra, A. | +10

7

High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations

enthalten in: International journal of molecular sciences | 2019

von Brodská, B. | Otevřelová, P. | Šálek, C. | +3

8

Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs

enthalten in: Cardiovascular & hematological disorders, drug targets | 2019

von Fuchs, O.

9

Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs

enthalten in: Cardiovascular & hematological disorders drug targets | 2019

von Fuchs, O.

10

Lenalidomide treatment in lower risk myelodysplastic syndromes-The experience of a Czech hematology center. (Positive effect of erythropoietin ± prednisone addition to lenalidomide in refractory or relapsed patients)

enthalten in: Leukemia research | 2018

von Jonasova, A. | Neuwirtova, R. | Polackova, H. | +9